Publications

Selected publications.

Samuli Eldfors, Joseph Saad, Nemo Ikonen, Disha Malani, Markus Vähä-Koskela, Bjørn T. Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A. Heckman. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia. Blood Adv 2024; 8 (7): 1621-1633. doi: https://doi.org/10.1182/bloodadvances.2023010435
Arnold Bolomsky, Juho J. Miettinen, Alina Malyutina, Andrej Besse, Julia Huber, Stefanie Fellinger, Helene Breid, Alun Parsons, Kristaps Klavins, J. Thomas Hannich, Stefan Kubicek, Jo Caers, Wolfgang Hübl, Martin Schreder, Niklas Zojer, Christoph Driessen, Jing Tang, Lenka Besse, Caroline A. Heckman, Heinz Ludwig. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv 2021; 5 (20): 4125–4139. doi: https://doi.org/10.1182/bloodadvances.2020003826
Liu Minxia, Wang Yinyin, Miettinen Juho J., Kumari Romika, Majumder Muntasir Mamun, Tierney Ciara, Bazou Despina, Parsons Alun, Suvela Minna, Lievonen Juha, Silvennoinen Raija, Anttila Pekka, Dowling Paul, O’Gorman Peter, Tang Jing, Heckman Caroline A. S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2021;9. doi: https://doi.org/10.3389/fcell.2021.723016
Miettinen JJ, Kumari R, Traustadottir GA, Huppunen M-E, Sergeev P, Majumder MM, Schepsky A, Gudjonsson T, Lievonen J, Bazou D, Dowling P, O`Gorman P, Slipicevic A, Anttila P, Silvennoinen R, Nupponen NN, Lehmann F, Heckman CA. Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. Cancers, 2021; 13(7):1527. doi: https://www.mdpi.com/1049176.
Kumar A, Adhikari S, Kankainen M and Heckman CA. Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma. Cancers, 2021, 13(6):1212. doi: https://www.mdpi.com/1028638.
Majumder MM, Leppä AM, Hellesøy M, Dowling P, Malyutina A, Kopperud R, Bazou D, Andersson E, Parsons A, Tang J, Kallioniemi O, Mustjoki S, O'Gorman P, Wennerberg K, Porkka K, Gjertsen BT, Heckman CA. Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types. Haematologica. 2019 Aug 22. pii: haematol.2019.217414. doi: 10.3324/haematol.2019.217414.
Malyutina A, Majumder MM, Wang W, Pessia A, Heckman CA, Tang J. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Comput Biol. 2019 May 20;15(5):e1006752. doi: 10.1371/journal.pcbi.1006752. eCollection 2019 May.
Kuusanmäki H, Leppä AM, Pölönen P, Dufva O, Kontro M, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica, 2019 Jul 11. doi: 10.3324/haematol.2018.214882.
Karjalainen R*, Liu M*, Kumar A, He L, Malani D, Parsons A, Kontro M, Kallioniemi O, Porkka K, Heckman CA. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML . Leukemia, 2019 Jun 7. doi: 10.1038/s41375-019-0504-y. *Equal contribution.
Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, Javarappa KK, Eldfros S, Schwaller J, Porkka K, Heckman CA. Dasatanib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia . Leukemia, 2019 Jun;33(6)1360-1372. doi: 10.1038/s41375-018-0327-2.
Javarappa KK, Tsallos D, Heckman CA. A multiplexed screening assay to evaluate chemotherapy-induced myelosuppression using healthy peripheral blood and bone marrow. SLAS Discovery. 2018 Aug; 23(7):697-696. doi: 10.1177/2472555218777968.
Kuusanmäki H, Dufva O, Parri E, van Adrichem AJ, Rajala H, Majumder MM, Yadav B, Parsons A, Chan WC, Wennerberg K, Mustjoki S, Heckman CA. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget, 2017 Oct 31;8(57)97516-97527. doi: 10.18632/oncotarget.22178.
Kumar A, Kankainen M, Parsons A, Kallioniemi O, Mattila P, Heckman CA. The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. BMC Genomics, 2017 Aug 17;18(1):629. doi: 10.1186/s12864-017-4039-1.
Kivioja J, Lopez Martí JM, Kumar A, Kontro M, Edgren H, Parsons A, Lundán T, Wolf M, Porkka K, Heckman CA. Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia. Leukemia & Lymphoma, 2017 Aug 4:1-8. doi: 10.1080/10428194.2017.1357174.
Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Safont MM, Porkka K, Aittokallio A, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA. JAK1/2 and BCL2 inhibitors synergize to counter-act bone marrow stromal cell-induced protection of AML. Blood, 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363.
Majumder MM*, Silvennoinen R*, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA. Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget, 2017. doi: 10.18632/oncotarget.17630. *Equal contribution.
Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia, 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314.
Ojamies P, Kontro M, Edgren H, Ellonen P, Lagström S, Almusa H, Miettinen T, Eldfors S, Tamborero D, Wennerberg K, Heckman C, Porkka K, Wolf M, Kallioniemi O. Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia. Leukemia, 2017 May;31(5):1048-1058. doi: 10.1038/leu.2016.286.
Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA*, Porkka K*. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia, 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. *Equal contribution.
Eldfors S, Kuusanmäki H, Kontro M, Majumder MM, Parsons A, Edgren H, Pemovska T, Kallioniemi O, Wennerberg K, Gökbuget N, Burmeister T, Porkka K, Heckman CA. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. Leukemia, 2017 Jan;31(1):51-57. doi: 10.1038/leu.2016.202.
Andersson EI, Kuusanmäki H, Bortoluzzi S, Lagström S, Parsons A, Rajala H, van Adrichem A, Eldfors S, Olson T, Clemente MJ, Laasonen A, Ellonen P, Heckman C, Loughran TP, Maciejewski JP, Mustjoki S. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia, 2016, 30: 1204-1208.
Pietarinen PO, Pemovska T, Kontro M, Yadav B, Mpindi JP, Andersson EI, Majumder MM, Kuusanmäki H, Koskenvesa P, Kallioniemi O, Wennerberg K, Heckman CA, Mustjoki S, Porkka K. Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. Blood Cancer J, 2015, 5: e309.
Elo LL, Karjalainen R, Ohman T, Hintsanen P, Nyman TA, Heckman CA, Aittokallio T. Statistical detection of quantitative protein biomarkers provides insights into signaling networks de-regulated in acute myeloid leukemia. Proteomics, 2014, 14: 2443-2453.
Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, Majumder MM, Malani D, Murumägi A, Knowles J, Porkka K, Heckman C, Kallioniemi O, Wennerberg K, Aittokallio A. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Reports, 2014, 4: 5193.
Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud, Ø, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagström S, Lohi O, Lundán T, Martí JM, Majumder MM, Parsons A, Pemovska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia, 28: 1738-1742, 2014.
Andersson EI, Rajala HL, Eldfors S, Ellonen P, Olson T, Jerez A, Clemente MJ, Kallioniemi O, Porkka K, Heckman C, Loughran TP Jr, Maciejewski JP, Mustjoki S. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J, 2013, 3: e168.
Pemovska T*, Kontro M*, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Lopez Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T‡, Heckman CA‡, Porkka K‡, Kallioniemi O‡, Wennerberg K‡. Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery, 2013, 3: 1415-1429. *‡ Equal contribution.
Rajala HL, Eldfors S, Kuusanmäki H, van Adrichem AJ, Olson T, Lagström S, Andersson EI, Jerez A, Clemente MJ, Yan Y, Zhang D, Awwad A, Ellonen P, Kallioniemi O, Wennerberg K, Porkka K, Maciejewski JP, Loughran TP Jr, Heckman C, Mustjoki S. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood, 2013, 121: 4541-4550. *Equal contribution.
Koskela HL*, Eldfors S*, A, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J Wennerberg K, Kallioniemi O, Porkka K Loughran TP Jr‡, Heckman CA‡, Maciejewski JP‡, Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med, 2012, 17: 1905-1913. *‡ Equal contribution.